Risk-benefit analysis of available treatments for schizophrenia

Psychiatric Times

Volumn 24, Issue 7 SUPPL. 1, 2007, Pages 27-30

  Citrome, Leslie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34347384176     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601 [see comments].
2. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223 [see comments].
3. McEvoy JP, Lieberman JA, Stroup TS et al. (2006), Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610 [see comment].
4. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164(3):415-427.
5. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622 [see comments].
6. Citrome L. Compelling or irrelevant? Differences between statistical and clinical significance. PsychEdUp. 2007;3(4):6-7.
7. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How To Practice and Teach EBM, 3rd Ed. New York: Elsevier Churchill Livingstone; 2005.
8. Fabre LF, Putman HP 3rd. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry. 1987;48(10):406-408.
9. Volavka J, Citrome L. Recent developments in antipsychotic use in adults. Psychiatric Times. 2003;20(5):33-35. Available at: www.psychiatrictimes. com. Accessed May 14, 2007.
10. Physicians' Desk Reference. Physicians' Desk Reference, 61st Ed. Montvale, N.J.: Thompson PDR; 2007.
11. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006;60(8):933-940 [see comments].
12. Cookson J, Keck PE Jr, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol. 2007;22(2):93-100.
13. Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol. 2006;21(5):267-273.
14. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof. 2002;25(2):210-224.